Definitive Healthcare Stock (NASDAQ:DH)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$0.85

52W Range

$0.80 - $4.70

50D Avg

$0.97

200D Avg

$2.19

Market Cap

$87.74M

Avg Vol (3M)

$324.48K

Beta

1.33

Div Yield

-

DH Company Profile


Definitive Healthcare Corp. (DH), operating through its various subsidiaries, offers specialized commercial intelligence solutions for the U.S. healthcare industry. The company's services furnish essential data on healthcare providers and their activities, enabling clients to navigate critical business processes, from the early stages of product development to strategic market entry planning and effective sales and marketing execution. Its sophisticated platform incorporates sixteen distinct intelligence modules. These modules are designed to support key functional domains such as sales optimization, marketing initiatives, clinical research, new product creation, strategic planning, human capital acquisition, and the oversight of physician networks. Definitive Healthcare caters to a broad spectrum of clients, including biopharmaceutical firms, medical device manufacturers, healthcare information technology companies, and direct healthcare providers. Additionally, its clientele extends to diverse organizations within the wider healthcare ecosystem, such as staffing and commercial real estate companies, financial institutions, and other related entities. Founded in 2011, Definitive Healthcare Corp. is headquartered in Framingham, Massachusetts.

Show More

Industry

Medical - Healthcare Information Services

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

782

IPO Date

Sep 15, 2021

Website

DH Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 25Dec 24Dec 22
Professional Services$9.30M$7.32M$5.63M
Subscription Services$232.22M$244.89M$217.02M

Fiscal year ends in Dec 25 | Currency in USD

DH Financial Summary


Dec 25Dec 24Dec 23
Revenue$241.52M$252.20M$251.41M
Operating Income$-224.27M$-710.82M$-329.80M
Net Income$-138.93M$-413.12M$-202.39M
EBITDA$-104.44M$-567.24M$-241.23M
Basic EPS$-1.30$-3.54$-1.79
Diluted EPS$-1.30$-3.54$-1.79

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts


Q1 26May 08, 26 | 12:00 AM
Q4 25Feb 27, 26 | 5:00 PM
Q3 25Nov 06, 25 | 5:00 PM

Peer Comparison


TickerCompany
SLPSimulations Plus, Inc.
NAKANakamoto Inc.
EDITEditas Medicine, Inc.
OMIOwens & Minor, Inc.
NRCNational Research Corporation
CABACabaletta Bio, Inc.
SPOKSpok Holdings, Inc.
TBRGTruBridge, Inc.
KYTXKyverna Therapeutics, Inc.
SOPHSOPHiA GENETICS S.A.